Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow

Cancer Epidemiology Biomarkers and Prevention

Volumn 8, Issue 2, 1999, Pages 159-166

  Sinués, Blanca ^a   Sáenz, María Angeles ^a   Lanuza, Javier ^a   Bernal, María Luisa ^a   Fanlo, Ana ^a   Juste, José Luis ^a   Mayayo, Esteban ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CAFFEINE DERIVATIVE;

ADULT; ARTICLE; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; MEASUREMENT; MICTURITION; MUTAGENICITY; NORMAL HUMAN; PRIORITY JOURNAL; SMOKING; TOBACCO; URINALYSIS; URINARY TRACT CANCER;

ADOLESCENT; ADULT; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CYTOCHROME P-450 CYP1A2; ENVIRONMENTAL EXPOSURE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUTAGENS; RHEOLOGY; SMOKING; THEOPHYLLINE; TIME FACTORS; URACIL; URIC ACID; URINATION; XANTHINES;

EID: 18844474725     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Shimada, T., Iwasaki, M., Martin, M. V., and Guengerich, F. P. Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA1535/ pSK 1002. Cancer Res., 49: 3218-3228, 1989.
2. Kitada, M., Taneda, M., Ohta, K., Nagashima, K., Itahashi, K., and Kamataki, T. Metabolic activation of aflatoxin B1 and 2-amino-3-methylimidazo[4,5-f]-quinoline by human adult and fetal liver. Cancer Res., 50: 2641-2645, 1990.
3. Gallagher, E. P., Wienkers, L. C., Stapleton, P. L., Kunze, K. L., and Eaton, D. L. Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin Bl. Cancer Res., 54: 101-108, 1994.
4. Campbell, M. E., Spielberg, S. P., and Kalow, W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin. Pharmacol. Ther., 42: 157-165, 1987.
5. Guengerich, F. P., and Shimada, T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol., 4: 391-407, 1991.
6. Fuhr, U., Anders, E-M., Mahr, G., Sörgel, F., and Staib, A. H. Inhibitory potency of quinolone antibacterial agents on cytochrome P4501A2 activity in vivo and in vitro. Antimicrob. Agents Chemother., 36: 942-948, 1992.
7. Brøsen, K., Skjelbo, E., Rasmussen, B. B., Poulsen, H. E., and Loft, S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol., 45: 1211-1214, 1993.
8. Kroemer, H. K., Gautier, J. C., Beaune, P., Henderson, C., Wolf, C. R., and Eichelbaum, M. Identification of P450 enzymes involved in the metabolism of verapamil in humans. Naunyn-Schmiedebergs Arch. Pharmakol., 348: 332-337, 1993.
9. Botsch, S., Gautier, J. C., Beaune, P., Eichelbaum, M., and Kroemer, H. K. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol. Pharmacol., 43: 120-126, 1993.
10. Kadlubar, F. F. Biochemical individuality and its implications for drug and carcinogen metabolism: recent insights from acetyltransferase and cytochrome P4501A2 phenotyping and genotyping in humans. Drug. Metab. Rev., 26: 37-46, 1994.
11. 2 breath test: dose response and route of N-demethylation in smokers and nonsmokers. Clin. Pharmacol. Ther., 32: 261-269, 1982.
12. Lambert, G. H., Schoeller, D. A., Humphrey, H. E. B., Kotake, A. N., Lietz, H., Campbell, M., Kalow, W., Spielberg, S. P., and Budd, M. The caffeine breath test and caffeine urinary metabolite ratios in the Michigan cohort exposed to polybrominated biphenyls: a preliminary study. Environ. Health. Perspect., 89: 175-181, 1990.
13. Parsons, W. D., and Neims, A. H. Effect of smoking on caffeine clearance. Clin. Pharmacol. Ther., 24: 40-45, 1978.
14. Murphy, T. L., McIvor, C., Yap, A., Cooksley, W. G. E., Halliday, J. W., and Powell, L. W. The effect of smoking on caffeine elimination: implications for its use as a semiquantitative test of liver function. Clin. Exp. Pharmacol. Physiol., 15: 9-13, 1988.
15. Butler, M. A., Iwasaki, M., Guengerich, F. P., and Kadlubar, F. F. Human cytochrome P-450PA (P-4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. USA, 86: 7696-7700, 1989.
16. Kalow, W., and Tang, B. K. The use of caffeine for enzyme assays: a critical appraisal. Clin. Pharmacol. Ther., 53: 503-514, 1993.
17. Tang, B. K., Grant, D. M., and Kalow, W. Isolation and identification of 5-acetylamino-6-formylamino-3-methyluracil as a major metabolite of caffeine in man. Drug Metab. Dispos.. 11: 218-220, 1983.
18. Gu, L., González, F. J., Kalow, W., and Tang, B. K. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics, 2: 73-77, 1992.
19. Kadlubar, F. F., Talaska, G., Butler, M. A., Teitel, C. H., Massengill, J. P., and Lang, N. P. Determination of carcinogenic arylamine N-oxidation phenotype in humans by analysis of caffeine urinary metabolites. In: M. L. Mendelsohn and R. J. Albertini (eds.), Mutation and the Environment. Part B: Metabolism, Testing Methods and Chromosomes, pp. 107-114. New York: John Wiley, 1990.
20. Butler, M. A., Lang, N. P., Young, J. F., Caporaso, N. E., Vineis, P., Hayes, R. B., Teitel, C. H., Massengill, J. P., Lawsen, M. F., and Kadlubar, F. F. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics, 2: 116-127, 1992.
21. Grant, D. M., Tang, B. K., and Kalow, W. Variability in caffeine metabolism. Clin. Pharmacol. Ther., 33: 591-602, 1983.
22. Carrillo, J. A., and Benitez, J. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin. Pharmacol. Ther., 55: 293-304, 1994.
23. Tang, B. K., Zhou, Y., Kadar, D., and Kalow, W. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics, 4: 117-124, 1994.
24. Landi, M. T., Zucchetti, C., Bernucci, I., Kadlubar, F. F., Tannembaum, S., Skipper, P., Bartsch, H., Malaveille, C., Shields, P., Caporaso, N. E., and Vineis, P. Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol. Biomarkers Prev., 5: 693-698, 1996.
25. Kadlubar, F. F., Young, J. F., Lang, N. P., Caporaso, N. P., Sinha, R., and Landi, M. T. Correspondence re: Letter to the Editor by B. K. Tang and W. Kalow on CYP1A2 phenotyping using caffeine. Cancer Epidemiol. Biomarkers and Prev., 5: 231, 1996. Cancer Epidemiol. Biomark. Prev., 5: 757-758, 1996.
26. Kadlubar, F. F., Young, J. F., Lang, N. P., Caporaso, N. P., Sinha, R., and Landi, M. T. Correspondence re: Letter to the Editor by B. K. Tang and W. Kalow on CYP1A2 phenotyping using caffeine. Cancer Epidemiol. Biomarkers and Prev., 5: 231, 1996. Cancer Epidemiol. Biomark. Prev., 5: 757-758, 1996.
27. Notarianni, L. J., Oliver, S. E., Dobrocky, P., Bennett, P. N., and Silverman, B. W. Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity. Br. J. Clin. Pharmacol, 39: 65-69, 1995.
28. Malaveille, C., Vineis, P., Estéve, J., Ohshima, H., Brun, G., Hautefeuille, A., Gallet, P., Ronco, G., Terracini, B., and Bartsch, H. Levels of mutagensin the urine of smokers of black and blond tobacco correlate with their risk of bladder cancer. Carcinogenesis (Lond.), 10: 577-586, 1989.
29. Bartsch, H., Caporaso, N., Coda, M., Kadlubar, F., Malaveille, C., Skipper, P., Talaska, G., Tannenbaum, S. R., and Vineis, P. Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers. J. Natl. Cancer Inst., 82: 1826-1831, 1990.
30. Sinués, B., Pérez, J., Bernal, M. L., Sáenz, M. A., Lanuza, J., and Bartolomé, M. Urinary mutagenicity and N-acetylation phenotype in textile industry workers exposed to arylamines. Cancer Res., 52: 4885-4889, 1992.
31. Sinués, B., Rueda, P., Benítez, J., Sáenz, M. A., Bernal, M. L., Lanuza, J., Alda, O., Tres, A., and Bartolomé, M. Thioether excretion, urinary mutagenicity, and metabolic phenotype in smokers. J. Toxicol. Environ. Health, 43: 327-338, 1994.
32. Arnott, M. A., Yamouchi, T., and Johnson, D. AHH in normal and cancer populations. In: A. C. Griffin, and C. R. Shaw (eds.), Carcinogen: Identification and Mechanisms of Action, pp. 147-156. New York: Raven Press, 1979.
33. Campbell, M. E., Grant, D. M., Inaba, T., and Kalow, W. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab. Dispos., 5: 237-249, 1987.
34. Kalow, W., and Tang, B. K. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin. Pharmacol. Ther., 49: 44-48, 1991.
35. Kalow, W., and Tang, B. K. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin. Pharmacol. Ther., 50: 508-519, 1991.
36. Vistisen, K., Poulsen, H. E., and Loft, S. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis (Lond.), 13: 1561-1568, 1992.
37. Tang, B. K., Kadar, D., Quian, L., Iriah, J., Yip, J., and Kalow, W. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin. Pharmacol. Ther., 49: 648-657, 1991.
38. Rost, K. L., and Roots, I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin. Pharmacol. Ther., 55: 402-411, 1994.
39. Yamasaki, E., and Ames, B. N. Concentration of mutagens from urine by adsorption with the nonpolar resin XAD-2: cigarette smokers have mutagenic urine. Proc. Natl. Acad. Sci. USA, 74: 3555-3559, 1977.
40. Malaveille, C., Brun, G., Kolar, G., and Bartsch, H. Mutagenic and alkylating activities of 3-methyl-1-phenyltriazenes and their possible role as carcinogenic metabolites of the parent dimethyl compounds. Cancer Res., 42: 1446-1453, 1982.
41. Kado, N. Y., Langley, D., and Eisenstadt, E. A simple modification of the Salmonella liquid-incubation assay. Increased sensitivity for detecting mutagens in human urine. Mutat. Res., 121: 25-32, 1983.
42. Maron, D. M., and Ames, B. N. Revised methods for the Salmonella mutagenicity test. Mutat. Res., 113: 173-215, 1983.
43. Rostami-Hodjegan, A., Nurminen, S., Jackson, P. R., and Tucker, G. T. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics, 6: 121-149, 1996.
44. Aramaki, S., Ishidaka, O., Suzuki, E., Momose, A., and Umemura, K. Theoretical relationship between the post-administration time and plasma or urinary concentration of a metabolite and the unchanged drug. Administration of caffeine to horses. Biol. Pharm. Bull., 19: 1341-1346, 1996.
45. Relling, M. V., Lin, J-S., Ayers, G. D., and Evans, W. E. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin. Pharmacol. Ther., 52: 643-658, 1992.
46. Tang, B. K., and Kalow, W. Assays for CYP1A2 by testing in vivo metabolism of caffeine in humans. Methods Enzymol., 272: 124-131, 1996.
47. Horn, E. P., Tucker, M. A., Lambert, G., Silverman, D., Zametkin, D., Sinha, R., Hartge, T., Landi, M. T., and Caporaso, N. E. A study of gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer. Cancer Epidemiol. Biomarkers Prev., 4: 529-533, 1995.
48. Nakajima, M., Yokoi, T., Mizutani, M., Shin, S., Kadlubar, F. F., and Kamataki, T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol. Biomarkers Prev., 3: 413-421, 1994.
49. Curvall, M., Romert, L., Norlén, E., and Enzell, C. R. Mutagen levels in urine from snuff users, cigarette smokers and nontobacco users. A comparison. Mutat. Res., 188: 105-110, 1987.
50. Bartsch, H., Malaveille, C., Friese, M., Kadlubar, F. F., and Vineis, P. Black (air-cured) and blond (flue-cured) tobacco cancer risk. IV: Molecular dosimetry studies implicate aromatic amines as bladder carcinogens. Eur. J. Cancer, 29A: 1199-1207, 1993.
51. 32P-Postlabelling analysis of DNA adducted with urinary mutagens from smokers of black tobacco. Carcinogenesis (Lond.), 11: 1307-1311, 1990.
52. DeMarini, D. M., Shelton, M. L., and Levine, J. G. Mutation spectrum of cigarette smoke condensate in Salmonella: comparison to mutations in smoking-associated tumors. Carcinogenesis (Lond.), 16: 2535-2542, 1995.
53. Erdinger, L., Schmezer, P., Razdan, R., Kumar, R., Spiegelhalder, B., Preussmann, R., and Siddiqi, M. Caffeine-derived N-nitroso compounds. III. Mutagenicity in S. typhimurium and in vitro induction of DNA single-strand breaks in rat hepatocytes by mononitrosocaffeidine and dinitrosocaffeidine. Mutat. Res., 292: 41-49, 1993.
54. Clonfero, E., Zordan, M., Cottica, D., Venier, P., Pozzoli, L., Cardin, E. L., Sarto, F., and Levis, A. G. Mutagenic activity and polycyclic aromatic hydrocarbon levels in urine of humans exposed to therapeutical coal tar. Carcinogenesis (Lond.), 7: 819-823, 1986.
55. Granella, M., and Clonfero, E. Sensitivity of different bacterial assays in detecting mutagens in urine of humans exposed to polycyclic aromatic hydrocarbons. Mutat. Res., 268: 131-137, 1992.
56. Adlkofer, F., Scherer, G., and Heller, W. D. Hydroxyproline excretion in urine of smokers and passive smokers. Prev. Med., 13: 670-679, 1984.
57. Raunio, H., Husgafvel-Pursiainen, K., Anttila, S., Hietanen, E., Hirvonen, A., and Pelkonen, O. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility: a review. Gene, 159: 113-121, 1995.
58. Smith, G., Stanley, L. A., Sim, E., Strange, R. C., and Wolf, C. R. Metabolic polymorphisms and cancer susceptibility. In: Cancer Surveys, Vol. 25: Genetics and cancer: A Second Look, pp. 27-65, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory. Imperial Cancer Research Fund, 1995.
59. Quattrochi, L. C., and Tukey, R. H. The human cytochrome CYP1A2 gene contains regulatory elements responsive to 3-methylcholanthrene. Mol. Pharmacol. 36: 66-71, 1989.
60. Pasquini, R., Monarca, S., Scassellati-Sforzolini, G., Savino, A., Bauleo, F. A., and Angeli, G. Urinary excretion of mutagens, thioethers and p-glucaric acid in workers exposed to bitumen fumes. Int. Arch. Occup. Environ. Health, 61: 335-340, 1989.
61. Nebert, D. W., Puga, A., and Vasiliou, V. Role of the Ah receptor and the dioxin-inducible [Ah] gene battery in toxicity, cancer, and signal transduction. Ann. NY Acad. Sci., 685: 624-640, 1993.
62. Hirvonen, A., Nylund, L., Kociba, P., Husgafvel-Pursiainen, K., and Vainio, H. Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers. Carcinogenesis (Lond.), 15: 813-815, 1994.